(VTAK) Catheter Precision, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(VTAK) Catheter Precision, Inc. Complete Analysis Pack
Catheter Precision’s Business Model, Simplified
Unlock the full strategic blueprint behind Catheter Precision, Inc.'s business model. This concise Business Model Canvas reveals how the company creates value, reaches customers, and builds revenue in a competitive medtech market. Ideal for investors, analysts, and strategists, the full version offers deeper insights you can use right away.
Partnerships
Hospital EP accounts
Catheter Precision’s hospital EP accounts are the core channel for the 3 main products, VIVO, LockeT, and Amigo, because electrophysiology labs are where teams test them and then move to routine use. In 2025, the sales path still depends on turning clinical interest in these hospital accounts into purchase orders, so each converted lab matters.
KOL physicians
KOL electrophysiologists validate Catheter Precision, Inc. products like VIVO and Amigo in real EP labs, giving direct feedback on workflow, usability, and clinical fit. That peer input helps refine the tools, build physician trust, and speed adoption through peer-to-peer recommendations.
Contract suppliers
Catheter Precision, Inc. relies on medical device suppliers and contract manufacturers for component sourcing, assembly, and production, because its EP products must stay available for procedural use. These partners help scale output without slipping on quality, and supply continuity matters because even a short delay can disrupt scheduled cases.
Field sales network
Catheter Precision, Inc. relies on direct sales personnel and distribution partners to cover roughly 6,100 U.S. hospitals and EP programs, while also handling product education and local account support. This field sales network helps build physician and hospital relationships without requiring a fully centralized sales force.
- Reaches U.S. EP programs fast
- Supports training and account coverage
- Builds local trust with hospitals
- Reduces internal sales overhead
Clinical research partners
Clinical sites, researchers, and regulatory consultants help Catheter Precision, Inc. generate case data, post-market feedback, and study support that physicians use to judge procedural proof and outcomes in electrophysiology. This matters because adoption in this field often depends on real-world evidence, not just product claims.
- Case data supports product positioning
- Post-market feedback improves use
- Studies build physician trust
Catheter Precision’s Growth Depends on EP Lab Validation
Catheter Precision, Inc. depends on hospital EP labs, KOL electrophysiologists, and clinical sites to validate VIVO, LockeT, and Amigo in real cases and turn physician trust into orders. It also leans on suppliers, contract manufacturers, and distributors to keep product flow steady across about 6,100 U.S. hospitals and EP programs.
| Partner | Role | Data |
|---|---|---|
| EP labs | Validation, adoption | ~6,100 U.S. targets |
What is included in the product
Detailed Word Document
A concise Business Model Canvas for Catheter Precision, Inc., mapping its real-world strategy, customers, channels, value proposition, and growth drivers.
Customizable Excel Spreadsheet
Quickly spot Catheter Precision, Inc.’s key business model pain points with a clear, editable one-page canvas.
Reference Sources
Provides a traceable source trail for Catheter Precision, Inc. that boosts credibility and helps decision-makers verify key claims fast.
Activities
EP product development
Catheter Precision, Inc. keeps EP product development at the core of its model, refining tools for arrhythmia care such as mapping, catheter control, and suture retention. That focus matters in a niche medtech market where even one cleared product can shape revenue access and clinical adoption.
Clinical validation
Catheter Precision’s clinical validation must prove VIVO works in real EP labs and hospital cases, because physician trust depends on accurate pre-procedure localization, not just lab data. In its 2024 reporting, the Company said commercialization depends on showing repeatable clinical performance, which is the proof point that supports adoption and sales.
Regulatory quality
Regulatory quality is core for Catheter Precision, Inc. because every FDA filing, design-control record, and quality-system check helps keep its catheter products sellable and trusted. In medical devices, post-market surveillance is not optional, and the FDA can flag issues fast: in 2025, the agency issued 1,200+ warning letters across regulated sectors, so tight compliance directly protects market access and product reliability.
Commercial education
Commercial education is a core adoption driver for Catheter Precision, Inc.: sales teams and clinical specialists must train physicians and hospital staff through in-services, live demos, and workflow coaching, since these capital and procedure products change operator technique at the point of care. This hands-on model matters because buy-in often depends on first-case success and repeatable use, not just the device spec.
- Physician training drives adoption
- In-services support hospital rollout
- Workflow education reduces use friction
- Clinical specialists improve technique
Post-market support
Post-market support keeps Catheter Precision, Inc. in the hospital workflow after placement: fast troubleshooting, user training, and feedback capture help protect live procedures and renew trust. In medtech, this matters because a 2025 FDA MAUDE review shows post-market issue reporting remains a major source of device-learning, so every support case can feed product updates and future upgrades.
- Fast response protects live cases
- Support helps retain hospital accounts
- Feedback drives product iteration
How Catheter Precision Turns FDA Approval Into Hospital Adoption
Catheter Precision’s key activities are EP product development, clinical validation, and FDA quality control. The Company also trains physicians and hospital staff, then uses post-market feedback to refine products and support repeat use.
| Activity | Why it matters |
|---|---|
| Clinical validation | Supports adoption |
| Regulatory quality | Protects market access |
| Training and support | Improves use in hospitals |
In medtech, these steps turn cleared devices into real clinical use and recurring accounts.
Delivered as Displayed
Business Model Canvas
This Catheter Precision, Inc. Business Model Canvas preview is the exact document you’ll receive after purchase, not a sample or mockup. What you see here is a real section of the final file, formatted and structured the same way as the complete version. After checkout, you’ll get full access to this same ready-to-use document for editing, presenting, or sharing.
Resources
3 product lines
VIVO, LockeT, and Amigo are Catheter Precision, Inc.'s 3 core commercial assets and the center of its electrophysiology identity. They drive current sales, service work, and the company’s pipeline, so product execution here directly shapes revenue and future development.
Fort Mill HQ
Catheter Precision's Fort Mill, South Carolina HQ is its U.S. command center for corporate management, commercial planning, and operational oversight. In FY2025, this central base supported execution across the company’s U.S. commercial and administrative work, anchoring day-to-day decisions from one site.
Engineering talent
Catheter Precision, Inc. relies on engineering talent, product developers, and clinical specialists to turn arrhythmia-care needs into usable EP devices and systems. That skill base matters because its portfolio is narrow and specialized, so each product needs precise design, testing, and clinician feedback to work in real procedures.
Regulatory system
Catheter Precision, Inc. depends on a strong regulatory system: quality management, design controls, and lifecycle documentation are what keep its devices commercialized under FDA rules. The FDA’s new Quality Management System Regulation takes effect on February 2, 2026, so compliance capability is now a direct operating asset, not just overhead.
- Design controls protect product safety
- Documentation supports FDA inspections
- Lifecycle management sustains commercialization
Brand and IP
Catheter Precision, Inc. brand names and proprietary device designs are key resources because they help physicians trust a small medtech company in a market where adoption is driven by clinical proof and reputation. In FY2025, that brand and IP base still mattered because it supports product differentiation and protects the Catheter Precision, Inc. portfolio from easy copying.
- Brand trust supports physician adoption.
- IP protects product differentiation.
- Proprietary designs defend the portfolio.
Catheter Precision’s Core Assets Drive FY2025 Execution
Catheter Precision, Inc.'s key resources are its three core EP products, its Fort Mill HQ, and its specialized engineering, clinical, and regulatory staff. In FY2025, these assets supported product execution, FDA-ready quality controls, and physician adoption across a narrow device portfolio.
| Resource | FY2025/2026 note |
|---|---|
| VIVO, LockeT, Amigo | 3 core commercial assets |
| HQ | Fort Mill, South Carolina |
| QMSR compliance | Effective Feb. 2, 2026 |
Value Propositions
Non-invasive mapping
VIVO gives Catheter Precision, Inc. a non-invasive 3D cardiac mapping value proposition, using a 12-lead ECG to help localize idiopathic ventricular arrhythmia origins before electrophysiology procedures. That can cut planning uncertainty for physicians and may help target intervention faster than moving straight to invasive mapping.
Pre-procedure localization
In 2025, Catheter Precision's pre-procedure localization targets patients with otherwise healthy hearts and idiopathic ventricular arrhythmias, helping teams pinpoint the source before the case starts. That can sharpen planning, cut trial-and-error mapping, and support a more targeted EP workflow.
Robotic catheter control
Amigo robotic catheter control gives operators precise, robotic-arm catheter manipulation, helping improve positioning consistency and a more controlled, repeatable workflow in electrophysiology cases. Catheter Precision, Inc. positions this value prop around reducing manual variability while supporting safer, more reproducible procedure execution.
Suture retention support
LockeT supports suture retention in procedural workflows by giving clinicians a practical way to secure closure-related tasks fast and with more stability. In Catheter Precision, Inc.'s Business Model Canvas, this fits a use case where speed, control, and repeatable handling matter at the bedside.
- Supports suture retention needs
- Built for quick clinical use
- Helps stabilize closure tasks
U.S. arrhythmia focus
Catheter Precision, Inc. targets U.S. cardiac arrhythmia care, so its value proposition is tightly tied to hospitals and electrophysiologists treating these patients. That narrow focus can fit a clinically clear need in a large U.S. market where atrial fibrillation alone affects millions of adults, but it also depends on winning adoption case by case.
- U.S. arrhythmia-only focus
- Hospitals and physicians as users
- Clinically relevant, narrow niche
Catheter Precision: Smarter EP Care for a 6.1M-Patient AF Market
Catheter Precision, Inc. sells tools that make EP care more targeted: VIVO helps localize idiopathic ventricular arrhythmias noninvasively before the case, while Amigo adds robotic catheter control for steadier handling. This fits a U.S. rhythm-care base where about 6.1 million people live with atrial fibrillation.
| Item | Value |
|---|---|
| 2025 U.S. AF | ~6.1M adults |
| VIVO use | Pre-EP localization |
| Amigo use | Robotic control |
Customer Relationships
Consultative selling
Catheter Precision, Inc. uses consultative B2B selling, so sales teams focus on workflow fit, clinical outcomes, and procedural use inside electrophysiology labs. That is the norm for hospital-based EP tools, where adoption depends on physician buy-in, training, and integration into hospital purchasing cycles.
On-site training
On-site training helps hospitals and physicians use Catheter Precision, Inc. EP tools with less friction, because hands-on in-service education builds confidence fast. That matters for VIVO and the Amigo robotic catheter system, where correct setup and workflow can directly affect adoption and day-one use.
Account management
Long-term account management helps Catheter Precision stay in the hospital after the first sale, supporting renewals, expansion, and repeat use. Medical device deals are often committee-led, with 3-10 stakeholders and review cycles that can run 6-18 months, so steady engagement keeps the company visible to clinicians, supply chain, and value analysis teams.
Technical support
Technical support is a key post-sale link for Catheter Precision, Inc. During procedures, fast help can cut device downtime and keep physician trust intact. In medtech, strong support is not optional; it protects clinical use and supports repeat adoption.
- Fast help during procedures
- Less downtime, more trust
- Supports post-sale retention
KOL advocacy
KOL advocacy can speed Catheter Precision, Inc.'s electrophysiology adoption because physicians often trust peer input more than sales claims. Working with respected clinical users can turn early wins into broader hospital acceptance, especially when each reference case lowers perceived procedural risk.
- KOLs build trust fast
- Peer proof drives adoption
- Clinical users widen reach
High-Touch Support Wins EP Lab Trust and Adoption
Catheter Precision, Inc. relies on high-touch customer ties: consultative sales, on-site training, and fast technical support. In EP labs, where buying often involves 3-10 stakeholders and 6-18 month review cycles, this steady contact helps win trust, speed adoption, and keep devices in use.
| Relationship | Value |
|---|---|
| Sales | Workflow fit |
| Training | Faster adoption |
| Support | Less downtime |
Channels
Direct sales force
Direct sales force is Catheter Precision, Inc.’s main route to hospitals and electrophysiology labs, letting reps shape product talks to physician needs and local buying rules. This high-touch model supports account development and matters in a market where one sale can depend on clinical review, committee approval, and site-specific workflows.
Clinical demonstrations
Clinical demonstrations let Catheter Precision, Inc. show device use in real procedures, so EP teams can judge workflow fit before buying. For workflow-shaping tools, one live in-service can do more than a brochure because it lets buyers see setup, handling, and clinical integration firsthand.
Medical conferences
EP and cardiology meetings give Catheter Precision, Inc. direct access to physicians, researchers, and hospital leaders in one place, so they work as a high-value awareness and lead-generation channel. Conference booths and talks also support education around catheter-based arrhythmia care and help turn clinical interest into sales conversations.
Digital education
Catheter Precision, Inc. uses digital education to let hospitals review product details, clinical use, and training before purchase; this matters because most hospital buying teams now compare vendors online first. In 2025/2026, web content and digital materials are a low-cost way to support discovery, shorten evaluation cycles, and explain VASCADE and other device features clearly.
- Supports online product discovery
- Helps clinical evaluation and training
- Reaches hospital buyers early
Distribution partners
Catheter Precision, Inc. uses external distributors and rep firms to extend U.S. coverage, so it can reach smaller accounts without building a heavy field team in every region. That keeps selling costs lighter and improves geographic efficiency, which matters for a small-cap medtech company with limited scale.
- Broader reach across U.S. accounts
- Lower fixed sales overhead
- Faster access to small hospitals
Catheter Precision’s Multi-Channel Sales Model Drives Hospital Adoption
Catheter Precision, Inc. sells mainly through direct reps, live clinical demos, EP meetings, digital education, and outside distributors, so it reaches both large hospital accounts and smaller sites. This mix supports a long sales cycle where one purchase can need physician buy-in, workflow proof, and committee approval.
| Channel | Role |
|---|---|
| Direct sales | Core hospital access |
| Clinical demos | Hands-on proof |
| EP meetings | Lead generation |
| Digital content | Early education |
| Distributors | Wider coverage |
Customer Segments
Electrophysiologists
Electrophysiologists are the core users of VIVO and Amigo, and their buying choice depends on map precision, faster workflow, and procedural confidence. With atrial fibrillation affecting about 12.1 million U.S. adults by 2030, even small gains in case speed and accuracy can drive adoption where they control the clinical decision.
EP hospitals
EP hospitals are Catheter Precision, Inc.’s core buyers because these sites run electrophysiology labs where the products are used. They judge clinical utility, staff training, and purchase economics before buying, so adoption depends on proof of workflow fit and measurable lab value.
These hospitals also shape repeat usage, since the same EP labs drive day-to-day ordering and procedure volume. Catheter Precision, Inc. must win both the clinical team and the hospital buyer to convert interest into purchase decisions.
Arrhythmia centers
Specialty arrhythmia centers fit Catheter Precision, Inc. well because they manage complex EP cases and pay for advanced mapping tools; atrial fibrillation affects about 33.5 million people worldwide, so demand for better localization stays high. These centers are a strong target for non-invasive solutions that can improve workflow and support ablation planning.
Outpatient EP programs
Outpatient EP programs are a strong fit for Catheter Precision, Inc. because ambulatory sites need fast, reliable catheter workflows that keep cases moving; in the U.S., there are 6,000+ ambulatory surgery centers, so even small gains in setup time, ease of use, and procedure flow can matter a lot.
- Throughput drives buying decisions
- Low training burden matters
- Price sensitivity is high
- Reliable workflow tools fit best
Value analysis teams
Value analysis teams are a key gatekeeper for Catheter Precision, Inc. because they decide if a product clears clinical value, cost, and rollout tests inside large health systems. In U.S. hospitals, these committees can make or break access across many sites, so winning them speeds adoption and drives commercial scale.
- Judge clinical value
- Review total cost
- Assess rollout impact
- Unlock health-system access
EP Buyers Want Speed, Proof, and Cost Discipline
Catheter Precision, Inc. serves EP hospitals, specialty arrhythmia centers, and outpatient EP programs, with value-analysis teams as the main buying gatekeeper. These buyers focus on workflow speed, low training burden, and clinical proof, since atrial fibrillation affects 12.1 million U.S. adults by 2030 and 33.5 million people worldwide.
| Segment | Key need | Buying test |
|---|---|---|
| EP hospitals | Lab fit | Clinical value |
| Arrhythmia centers | Precision | Advanced cases |
| Outpatient EP | Speed | Throughput |
| Value teams | Cost | Rollout impact |
Cost Structure
R&D spend
Catheter Precision, Inc. treats R&D as a core cost because engineering, prototyping, and product refinement must run continuously across multiple device lines. This spend keeps the portfolio clinically competitive, and the latest 2025/2026 filing should be used to size its exact dollar load and margin impact.
Clinical evidence
Clinical evidence is a real cost driver for Catheter Precision, Inc. because studies, testing, and data generation can run into the low millions per program, while physician-led buying still depends on proof of safety, efficacy, and workflow fit. That spend helps build market trust and adoption, and it matters more in hospitals where one bad clinical signal can slow purchases fast.
Regulatory and quality
Regulatory and quality costs are fixed for Catheter Precision, Inc. because FDA’s Quality Management System Regulation (QMSR) takes effect on Feb. 2, 2026, so the company must keep validation, audits, documentation, and regulatory support in place. These controls raise overhead, but they protect market access and cut recall and compliance risk in a market where one missed step can stop sales.
Manufacturing and COGS
Catheter Precision, Inc. has a hardware-heavy cost base, so device production, component sourcing, assembly, and logistics drive COGS. For electromechanical products, tight production controls and quality checks matter, while inventory can trap cash until units ship.
- Components and assembly set unit cost
- Quality control raises fixed overhead
- Freight and warehousing add cash burn
- Inventory ties up working capital
Sales, G&A
Sales, G&A for Catheter Precision, Inc. are recurring costs tied to commercial staffing, marketing, and general corporate overhead. As a public company, it also bears reporting and administrative costs, and these expenses stay in place to support product commercialization and day-to-day operations.
- Recurring sales and marketing spend
- Public-company reporting costs
- General corporate overhead
- Supports commercialization
Catheter Precision’s Fixed Costs Stay Heavy Before Sales Scale
Catheter Precision, Inc. carries a lean but fixed-heavy cost base: R&D, clinical work, FDA QMSR compliance from 2026-02-02, and public-company SG&A all stay on even before sales scale. Manufacturing, sourcing, freight, and inventory also pressure cash because hardware costs hit upfront.
| Cost item | 2025/2026 driver |
|---|---|
| R&D | Continuous product work |
| Clinical/regulatory | QMSR starts 2026-02-02 |
| COGS/logistics | Hardware, assembly, freight |
| SG&A | Sales and public filing costs |
Revenue Streams
VIVO sales
VIVO sales are Catheter Precision, Inc.’s core revenue stream, driven by system placements in hospital settings. The VIVO platform supports complex procedures with high-technology mapping, so each sale ties to a procedure-support use case, not just device volume.
Amigo sales
Amigo sales can generate capital equipment revenue when hospitals and EP labs buy the Amigo Remote Catheter System to improve catheter control precision. In Catheter Precision, Inc.'s latest reported filings, this is a hardware-led stream, so revenue should rise with unit placements and repeat procedure use rather than with disposable pull-through.
LockeT sales
Catheter Precision, Inc.’s LockeT sales generate device revenue on each unit sold, and the product fits suture-retention steps in procedural workflows. Even with a small device base, this transaction-based model can still produce steady cash flow because revenue scales with procedure volume, not subscriptions.
Accessories and replacements
Catheter Precision, Inc. does not disclose a separate 2025/2026 line item for accessories and replacements, but this stream matters because medtech installs can drive repeat sales of consumables tied to the base system. In the latest public filings I could verify, the company’s total revenue remained very small, so even modest repeat orders can matter to cash flow.
- Repeat sales can lift lifetime value.
- Consumables support installed-base demand.
- Public filings do not break this out.
Service and support
Service and support can add recurring revenue through training, maintenance, and technical help, either sold on their own or bundled with catheter sales. For Catheter Precision, Inc., this matters because EP labs often need onboarding and in-procedure support, so the service layer can raise retention and product use while strengthening the commercial value proposition.
- Training lifts adoption in EP labs.
- Maintenance supports repeat revenue.
- Technical support improves retention and use.
- Bundled service can raise deal value.
Catheter Precision: Device Sales Drive Revenue, Recurring Upside Still Limited
Catheter Precision, Inc. makes money mainly from VIVO, Amigo, and LockeT device sales, with extra upside from accessories and service tied to the installed base. Latest filings show no separate 2025/2026 breakout for recurring revenue, so unit placements still drive most sales.
| Stream | 2025/2026 read |
|---|---|
| VIVO | Core system sales |
| Amigo | Capital equipment placements |
| LockeT | Per-unit device revenue |
| Service | Not separately disclosed |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.